このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Effects of Bubble-PEP After Open Heart Surgery on Blood Gases, Dyspnea, Secretion Status, and Pain (BUBBLE-PEP)

2026年11月16日 更新者:Hamide Erkan、Afyonkarahisar Health Sciences University

The Effect of Bubble-PEP Intervention After Open Heart Surgery on Arterial Blood Gas, Dyspnea, Secretion Status, and Pain: A Randomized Controlled Study

This randomized controlled study aims to evaluate the effects of Bubble Positive Expiratory Pressure (Bubble-PEP) therapy on arterial blood gas parameters, dyspnea, respiratory secretion status, and pain in patients undergoing open-heart surgery.

The study will be conducted in the Cardiovascular Surgery Department and Intensive Care Unit of Afyonkarahisar Health Sciences University Health Research and Application Center, Türkiye. A total of 92 adult patients undergoing coronary artery bypass grafting or heart valve surgery will be included. Participants will be randomly assigned to an intervention group (n=46) or a control group (n=46) using stratified block randomization based on surgical procedure.

Both groups will receive standard postoperative care, including breathing exercises, chest percussion, and incentive spirometry. In addition to standard care, the intervention group will receive Bubble-PEP therapy twice daily for three consecutive days following extubation. Each session will consist of three sets of 10 expirations.

Arterial blood gas parameters, dyspnea, respiratory secretion status, and pain will be assessed at baseline, during follow-up, and after completion of the intervention. Patient satisfaction will also be evaluated.

The study aims to determine whether adding Bubble-PEP therapy to standard postoperative care improves respiratory outcomes and contributes to evidence-based nursing care following open-heart surgery.

調査の概要

状態

まだ募集していません

詳細な説明

Study Design and Setting This study is designed as a randomized controlled trial to investigate the effects of Bubble Positive Expiratory Pressure (Bubble-PEP) therapy on arterial blood gas parameters, dyspnea, respiratory secretion status, and pain following open-heart surgery.

The study will be conducted in the Cardiovascular Surgery Department and Intensive Care Unit of Afyonkarahisar Health Sciences University Health Research and Application Center, Türkiye. Ethical approval was obtained from the Non-Interventional Scientific Research Ethics Committee of Afyonkarahisar Health Sciences University on October 2, 2026 (Decision No. 740).

Participants and Sample Size The study will include 92 adult patients undergoing coronary artery bypass grafting (CABG) or heart valve surgery, with 46 patients assigned to each group.

The sample size was calculated using G*Power 3.1.9.7, based on an effect size of 0.659 for PaO2, a significance level of 0.05, and 80% statistical power. The initial sample size was 76 participants, which was increased to 92 to account for an anticipated 20% dropout rate.

Eligible participants will be aged 18 years or older, have undergone CABG or heart valve surgery, be extubated and hemodynamically stable, be able to communicate in Turkish, and provide informed consent.

Randomization and Blinding Participants will be allocated to intervention and control groups in a 1:1 ratio using stratified block randomization according to surgical type (CABG or heart valve surgery).

Computer-generated randomization lists will be prepared by an independent researcher who is not involved in intervention delivery or outcome assessment. Group allocation will be implemented using sequentially numbered, sealed envelopes.

Due to the nature of the intervention, participants and the researcher administering Bubble-PEP therapy cannot be blinded. However, outcome assessments will be conducted by an independent assessor blinded to group allocation. The statistician will also remain blinded to group identity until completion of the analysis.

Control Group Participants in the control group will receive standard postoperative care, including breathing exercises, chest percussion, and incentive spirometry.

Intervention Group Participants in the intervention group will receive Bubble-PEP therapy in addition to standard postoperative care.

The Bubble-PEP apparatus will consist of a 1.5-liter plastic bottle filled with water to a depth of 10 cm and a tube approximately 80 cm long with an internal diameter of 8 mm. A separate bottle and tube will be provided for each participant.

Bubble-PEP therapy will begin after extubation, once the patient is conscious, hemodynamically stable, and considered clinically suitable by the treating physician.

During the intervention, patients will be placed in an upright sitting position and instructed to inhale deeply through the nose and then exhale slowly, continuously, and in a controlled manner through the tube submerged in water.

The intervention will be administered twice daily, in the morning and afternoon, on the first, second, and third days after extubation. Each session will consist of three sets of 10 expirations, totaling 30 expirations per session.

Outcome Measurements

The primary outcome measures will include:

Arterial blood gas parameters: PaO2, PaCO2, pH, HCO3-, base excess (BE), and oxygen saturation (SpO2).

Dyspnea severity assessed using the Modified Borg Dyspnea Scale. Respiratory secretion status and cough effectiveness assessed using a researcher-developed postoperative respiratory secretion and cough effectiveness assessment form.

Secondary outcome measures will include:

Pain intensity assessed using the Visual Analog Scale (VAS). Patient satisfaction assessed using a visual patient satisfaction scale.

Data Collection and Assessment Schedule Preoperative demographic and clinical data will be collected after obtaining written informed consent. Preoperative dyspnea and pain assessments will also be performed.

The first calendar day following extubation will be designated as Day 1 (G1). Baseline postoperative assessments will be performed on Day 1, before the first Bubble-PEP session, preferably between 09:00 and 10:00, provided that at least six hours have elapsed since extubation and the patient is hemodynamically stable.

Follow-up assessments will be performed on Days 2 and 3 (G2 and G3), between 09:00 and 10:00, before the daily intervention.

The final assessment will be performed on Day 4 (G4), between 09:00 and 10:00, following completion of the three-day intervention period. Patient satisfaction will also be evaluated during the final assessment.

Arterial blood gas results obtained as part of routine clinical care will be recorded from patient records.

Statistical Analysis Data will be analyzed using SPSS software. Descriptive statistics will include frequencies, percentages, means, and standard deviations.

Depending on the distribution of the data, independent-samples t-tests or Mann-Whitney U tests will be used for between-group comparisons. Paired t-tests or Wilcoxon signed-rank tests will be used for within-group comparisons.

Repeated-measures analysis of variance or Friedman tests will be used to evaluate changes over time, as appropriate. Exploratory subgroup analyses based on surgical type may be performed if the sample size is sufficient.

Statistical significance will be set at p < 0.05.

研究の種類

介入

入学 (推定)

92

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Centre
      • Afyonkarahisar、Centre、トルコ(Türkiye)、03100
        • Afyonkarahisar University of Health Sciences

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Having undergone Coronary Artery Bypass Graft (CABG) or heart valve surgery,
  • Being 18 years of age or older,
  • Not having undergone postoperative revision surgery,
  • Having no neurological or severe cognitive impairment, and no postoperative delirium,
  • Being extubated and hemodynamically stable,
  • Being able to communicate in Turkish,
  • Being willing to participate in the research.

Exclusion Criteria:

  • Having undergone a surgical procedure other than CABG or heart valve surgery,
  • Patients who require revision surgery during the postoperative period,
  • Patients with neurological or severe cognitive impairment,
  • Patients experiencing postoperative delirium,
  • Individuals aged 18 years or younger,
  • Patients who have not been extubated,
  • Patients who are hemodynamically unstable,
  • Individuals with whom it is not possible to communicate in Turkish, or those who are unwilling to participate in the study.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:支持療法
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:Bubble-PEP Intervention Group

Patients in the intervention group will receive Bubble Positive Expiratory Pressure (Bubble-PEP) therapy in addition to routine postoperative care following open-heart surgery. I will evaluate the intervention's effects on arterial blood gas parameters, dyspnea, secretion status, and pain.

A researcher-prepared Bubble Positive Expiratory Pressure (Bubble-PEP) device will be used in addition to standard postoperative care.

The device will consist of a 1.5-liter plastic bottle filled with water to a depth of 10 cm and an approximately 80-cm-long tube with an internal diameter of 8 mm. Each patient will be provided with an individual bottle and tube.

Bubble-PEP therapy will be initiated after extubation when the patient is conscious, hemodynamically stable, and considered clinically suitable by the treating physician.

During the intervention, the patient will be placed in an upright sitting position and instructed to inhale deeply through the nose, followed by slow, controlled, and continuous exhalation through the tube submerged in water.

The intervention will be administered twice daily, in the morning and afternoon, on the first, second, and third days after extubation. Each session will consist of three sets of 10 expirations, totaling 30 expirations per session.

他の名前:
  • Bottle Positive Expiratory Pressure (Bottle-PEP)
介入なし:Control Group

Patients in the control group will receive routine postoperative care following open-heart surgery, with no additional interventions applied. I will assess arterial blood gas parameters, dyspnea, secretion status, and pain.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in Arterial Oxygen Partial Pressure(PaO₂)
時間枠:Days 1, 2, and 3 post-extubation

Arterial oxygen partial pressure(PaO₂) will be measured using arterial blood samples obtained from patients following open-heart surgery. Changes in PaO₂ levels will be evaluated and compared between the Bubble-PEP intervention group and the control group.

Days 1, 2, and 3 post-extubation
Change in Arterial Carbon Dioxide Partial Pressure(PaCO₂)
時間枠:Days 1, 2, and 3 post-extubation

Arterial carbon dioxide partial pressure (PaCO₂) will be measured using arterial blood samples obtained from patients following open-heart surgery. Changes in PaCO₂ levels will be evaluated and compared between the Bubble-PEP intervention group and the control group.

Days 1, 2, and 3 post-extubation
Change in Arterial Blood pH
時間枠:Days 1, 2, and 3 post-extubation

Arterial blood pH will be measured using arterial blood samples obtained from patients following open-heart surgery. Changes in arterial blood pH will be evaluated and compared between the Bubble-PEP intervention group and the control group.

Days 1, 2, and 3 post-extubation
Change in Arterial Oxygen Saturation (SaO₂)
時間枠:Days 1, 2, and 3 post-extubation

Arterial oxygen saturation (SaO₂, %) will be measured using arterial blood samples obtained from patients following open-heart surgery. Changes in SaO₂ levels will be evaluated and compared between the Bubble-PEP intervention group and the control group.

Days 1, 2, and 3 post-extubation
Change in Arterial Bicarbonate Level (HCO₃-)
時間枠:Days 1, 2, and 3 post-extubation

Arterial bicarbonate levels (HCO₃-, mmol/L) will be measured using arterial blood samples obtained from patients following open-heart surgery. Changes in HCO₃- levels will be evaluated and compared between the Bubble-PEP intervention group and the control group.

Days 1, 2, and 3 post-extubation
Change in Arterial Blood Base Excess (BE)
時間枠:Days 1, 2, and 3 post-extubation

Arterial blood base excess (BE, mmol/L) will be assessed using arterial blood samples obtained from patients following open-heart surgery. Changes in BE levels will be evaluated and compared between the Bubble-PEP intervention group and the control group.

Days 1, 2, and 3 post-extubation
Change in Dyspnea Severity
時間枠:Days 1, 2, and 3 post-extubation

Dyspnea severity will be assessed in patients following open heart surgery using a standardized dyspnea assessment scale. Changes in dyspnea scores will be evaluated and compared between the Bubble-PEP intervention group and the control group. Higher scores will indicate greater dyspnea severity.

Days 1, 2, and 3 post-extubation
Change in Respiratory Secretion Status
時間枠:Days 1, 2, and 3 post-extubation

Respiratory secretion status will be assessed in patients following open heart surgery to evaluate the effects of Bubble Positive Expiratory Pressure (Bubble-PEP) therapy on airway secretion clearance. Changes in secretion status will be evaluated and compared between the intervention and control groups.

Days 1, 2, and 3 post-extubation

二次結果の測定

結果測定
メジャーの説明
時間枠
Change in Postoperative Pain Intensity
時間枠:Days 1, 2, and 3 post-extubation

Postoperative pain intensity will be assessed using the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity. Changes in pain scores will be compared between the Bubble-PEP intervention group and the control group.

Days 1, 2, and 3 post-extubation

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年11月16日

一次修了 (推定)

2027年4月1日

研究の完了 (推定)

2027年8月30日

試験登録日

最初に提出

2026年11月10日

QC基準を満たした最初の提出物

2026年11月16日

最初の投稿 (実際)

2026年11月18日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月18日

QC基準を満たした最後の更新が送信されました

2026年11月16日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Individual participant data will not be made publicly available or shared with other researchers. The study involves patients undergoing open-heart surgery, and participant confidentiality and data privacy will be maintained in accordance with the approved research protocol and applicable ethical and data protection requirements.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する